News

Zealand Pharma's Kv1.3 blocker ZP9830 clears Phase 1 safety hurdle

What's the deal? Zealand Pharma, the Danish biotech focused on metabolic and immunological diseases, announced on 19 October 2026 positive topline results from the multiple ascending dose part of its first-in-human Phase 1 trial for ZP9830, a drug candidate that blocks an ion channel called Kv1.3 on T-cells, a type of white blood cell central to autoimmunity.

What the data showed: ZP9830 was safe and well tolerated over four weeks of dosing with follow-up to day 41. There were no dose-limiting safety findings, and all treatment-emergent adverse events were non-serious and mild. No clinically relevant changes were seen in vital signs, ECG recordings or physical examinations.

Why it matters: Kv1.3 is a potassium ion channel that is switched on mainly in “effector memory” T-cells — the immune cells that drive the tissue damage seen in many autoimmune and chronic inflammatory diseases. Blocking it is intended to quiet those cells while leaving the rest of the immune system intact, so the drug could in principle be used across a broad range of cell-mediated autoimmune diseases. Zealand has now started a Phase 1b trial testing ZP9830 in people with plaque psoriasis, and plans a Phase 2 trial in a further autoimmune disease in the first half of 2027. The single ascending dose part of this Phase 1 trial had already returned positive topline results earlier in 2026.

Read more: Zealand Pharma via GlobeNewswire, 19 October 2026

More top stories